Dr Alexander Niessner speaks to Cardio Debate and Radcliffe Cardiology about anticoagulants in atrial fibrillation and how to identify high risk patients during the ESC Congress 2015 in London, UK.
Anticoagulants in atrial fibrillation – how to identify high risk patients
Related articles
05/21/2018 - Atrial fibrillation patterns, arrhythmia progression and clinical outcomes: Examining the links - Sian Claire Owen, medical journalist for Cardio Debate, UK
02/05/2018 - Uninterrupted apixaban therapy vs. warfarin during AF ablation: A question of safety and efficacy - Dr Amelia Carro Hevia, Spain
10/22/2017 - DOACs ‘overcome many of warfarin’s problems’ – Dr James Uprichard - Dr James Uprichard, St George's University Hospitals NHS Trust, UK
03/13/2017 - Challenges of using DOACs in everyday practice – Cardiology Update 2016 - Dr Irina Savelieva, St George's Hospital, SGUL, UK
02/20/2017 - Catheter ablation in Atrial Fibrillation – Cardiology Update 2016 - Dr Riccardo Cappato, Humanitas Hospital, Milan, Italy
02/13/2017 - DOACs in real life clinical practice: the impact of “antidotes” – Cardiology Update 2016 - Dr Steve Austin, St George's Hospital, London, UK
11/14/2016 - Screening for AF to prevent stroke: The AF Screen International Collaboration - Prof Benedict Freedman, University of Sydney, Australia
09/26/2016 - Anticoagulation in Atrial Fibrillation patients prone to fall – What to do? - Prof Juan Carlos Kaski, St George's, University of London, UK
06/13/2016 - Chronic Heart Failure – The Management of Comorbidities: atrial fibrillation - Dr Amelia Carro Hevia, Instituto Corvilud, Spain
04/18/2016 - Atrial fibrillation - Dr Irina Savelieva, St George's, University of London, UK
Leave a Reply
You must be logged in to post a comment.